Human Genome Sciences licenses gene to Amgen

By Lisa Kerner

Erie, Pa., Jan. 9 - Human Genome Sciences, Inc. announced a license agreement with Amgen Inc., giving Amgen exclusive worldwide rights to commercialize therapeutic biological products for human use based on a human gene discovered by Human Genome Sciences.

The potential applications for these products include autoimmune diseases, immune deficiencies or suppression, and cancer.

Amgen also acquires non-exclusive worldwide rights for the commercialization of diagnostic products for human use based on the same gene.

For its part, Human Genome Sciences will receive from Amgen an upfront payment, annual fees, development milestone payments and royalties on annual net sales.

"This agreement is one more step in our monetization of Human Genome Sciences assets and in providing access to our technology to those companies who share our goal of developing gene-based therapeutic and diagnostic products for use in the treatment of serious diseases," said H. Thomas Watkins, president and chief executive officer, Human Genome Sciences, in a news release.

Human Genome Sciences, based in Rockville, Maryland, develops protein and antibody drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.